Verve Therapeutics, Inc. (VERV)

USD 5.09

(-9.27%)

Market Cap (In USD)

430.93 Million

Revenue (In USD)

11.75 Million

Net Income (In USD)

-200.06 Million

Avg. Volume

1.43 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.305-19.34
PE
-
EPS
-
Beta Value
1.76
ISIN
US92539P1012
CUSIP
92539P101
CIK
1840574
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sekar Kathiresan M.D.
Employee Count
-
Website
https://www.vervetx.com
Ipo Date
2021-06-17
Details
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.